On May 21, 2019 RhoVac reported that a summary of the collaboration with Lund University has been published prior to the upcoming ASCO (Free ASCO Whitepaper) Annual Meeting (American Society of Clinical Oncology) held in Chicago on May 31-June 4 (Press release, RhoVac, MAY 21, 2019, View Source [SID1234555930]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The primary objective of the study was to investigate whether RhoC is expressed to a greater extent in cancer stem cells in prostate cancer induced metastases in radiation exposed mice. The metastasis tissues were harvested, sectioned and analyzed by immunohistochemical methods, comparing the presence of different biomarkers. The biomarkers analyzed were for RhoC, Adenoreceptor (AR), CD 166 (cancer stem cell) and Ki67 (proliferation). The results showed, that RhoC is expressed to a greater extent in the metastatic tissue and, and that there is a subpopulation of RhoC-positive cells in the metastases, which are double-labeled with CD166 to the cancer stem cells.

Anders Ljungqvist, CEO: – It was satisfying to see that these results confirmed that RhoC was expressed to a greater extent in the metastasis tissue than in the tumor, and that a subpopulation of the RhoC-positive cells also has cancer stem cell character.